Weekly low dose paclitaxel and cisplatin as first-line chemotherapy for advanced non-small cell lung cancer.
作者： Sang-We Kim , Cheolwon Suh , Sang Do Lee , Woo Sung Kim , Dong Soon Kim
DOI: 10.1016/S0169-5002(03)00192-2
关键词:
摘要: Abstract The efficacy and toxicity of weekly low dose chemotherapy using paclitaxel cisplatin were evaluated in 22 chemotherapy-naive patients with non-small cell lung cancer (NSCLC). Paclitaxel (40 mg/m 2 by 1 h infusion) (20 administered without interruption. With a median 16 cycles chemotherapy, objective response rate was 40.9% (95% confidence interval, 18.6–63.2%). Stable disease progressive categories accounted for 40.9 18.2%, respectively. duration 3 months (1–12 months). Myelosuppression not noted non-hematologic toxicities mild. This study indicates that could be given safely to the NSCLC showed promising rate.
sci-hub.se 参考文章(27)
Sareh Parangi, Robert J. D'Amato, Nancy Klauber, Ernest Hamel, Evelyn Flynn, Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Research. ,vol. 57, pp. 81- 86 ,(1997)
L Gianni, C M Kearns, A Giani, G Capri, L Viganó, A Lacatelli, G Bonadonna, M J Egorin, Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. Journal of Clinical Oncology. ,vol. 13, pp. 180- 190 ,(1995) , 10.1200/JCO.1995.13.1.180
Diane Fairclough, David Cella, John Kugler, Eric Rowinsky, Michael Jiroutek, David Johnson, Philip Bonomi, KyungMann Kim, Comparison of Survival and Quality of Life in Advanced Non–Small-Cell Lung Cancer Patients Treated With Two Dose Levels of Paclitaxel Combined With Cisplatin Versus Etoposide With Cisplatin: Results of an Eastern Cooperative Oncology Group Trial Journal of Clinical Oncology. ,vol. 18, pp. 623- 631 ,(2000) , 10.1200/JCO.2000.18.3.623
M S Georgiadis, B S Schuler, J E Brown, L V Kieffer, S M Steinberg, W H Wilson, C H Takimoto, M J Kelley, B E Johnson, Paclitaxel by 96-hour continuous infusion in combination with cisplatin : A phase I trial in patients with advanced lung cancer Journal of Clinical Oncology. ,vol. 15, pp. 735- 743 ,(1997) , 10.1200/JCO.1997.15.2.735
Judah Folkman, Birgit M. Kräling, Catherine E. Butterfield, Blair Marshall, Timothy Browder, Michael S. O’Reilly, Bin Shi, Antiangiogenic Scheduling of Chemotherapy Improves Efficacy against Experimental Drug-resistant Cancer Cancer Research. ,vol. 60, pp. 1878- 1886 ,(2000)
Shunichiro Ota, Toru Sugiyama, Kimio Ushijima, Kan Komai, Keizo Fujiyoshi, Nobuyuki Hirai, Takashi Nishida, Toshiharu Kamura, Successful treatment of two patients with recurrent endometrial cancer by weekly paclitaxel. Cancer Letters. ,vol. 160, pp. 9- 12 ,(2000) , 10.1016/S0304-3835(00)00548-6
Ryungsa Kim, Akihiko Osaki, Tetsuya Toge, Pharmacokinetic and biochemical analysis in the treatment of weekly paclitaxel in relapsed breast cancer Oncology Reports. ,vol. 8, pp. 1171- 1176 ,(2001) , 10.3892/OR.8.5.1171
Y. Kano, Miyuki Akutsu, Saburo Tsunoda, Kenichi Suzuki, Yasuo Yazawa, In vitro schedule-dependent interaction between paclitaxel and cisplatin in human carcinoma cell lines Cancer Chemotherapy and Pharmacology. ,vol. 37, pp. 525- 530 ,(1996) , 10.1007/S002800050424
Gokul C. Das, David Holiday, Rafael Gallardo, Charles Haas, Taxol-induced cell cycle arrest and apoptosis: dose–response relationship in lung cancer cells of different wild-type p53 status and under isogenic condition Cancer Letters. ,vol. 165, pp. 147- 153 ,(2001) , 10.1016/S0304-3835(01)00404-9
George Koumakis, Matina Demiri, Vassilios Barbounis, Michail Vassilomanolakis, Emmanuel Gontikakis, Philip Pamouksoglou, Jabrahel Dahabre, Anna P Efremidis, Is weekly paclitaxel superior to paclitaxel given every 3 weeks? Results of a phase II trial Lung Cancer. ,vol. 35, pp. 315- 317 ,(2002) , 10.1016/S0169-5002(01)00441-X